221 related articles for article (PubMed ID: 26806350)
1. Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.
Naguib YW; Lansakara-P D; Lashinger LM; Rodriguez BL; Valdes S; Niu M; Aldayel AM; Peng L; Hursting SD; Cui Z
Neoplasia; 2016 Jan; 18(1):33-48. PubMed ID: 26806350
[TBL] [Abstract][Full Text] [Related]
2. A solid lipid nanoparticle formulation of 4-(N)-docosahexaenoyl 2', 2'-difluorodeoxycytidine with increased solubility, stability, and antitumor activity.
Valdes SA; Alzhrani RF; Rodriguez A; Lansakara-P DSP; Thakkar SG; Cui Z
Int J Pharm; 2019 Oct; 570():118609. PubMed ID: 31415878
[TBL] [Abstract][Full Text] [Related]
3. 4-(N)-Docosahexaenoyl 2', 2'-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent.
Hufnagel S; Xu H; Colemam MF; Valdes SA; Liu KA; Hursting SD; Cui Z
Cancer Chemother Pharmacol; 2022 Jan; 89(1):59-69. PubMed ID: 34698902
[TBL] [Abstract][Full Text] [Related]
4. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
Xu Y; Meng H; Du F; Lu W; Liu S; Huang J; Yu J
Int J Pharm; 2015 Nov; 495(2):792-7. PubMed ID: 26410754
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of the Short-Term Toxicity of 4-(N)-Docosahexaenoyl 2´, 2´- Difluorodeoxycytidine (DHA-dFdC).
Valdes S; Naguib YW; Finch RA; Baze WB; Jolly CA; Cui Z
Pharm Res; 2017 Jun; 34(6):1224-1232. PubMed ID: 28352993
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells.
Graziadei I; Kelly T; Schirmer M; Geisen FH; Vogel W; Konwalinka G
J Hepatol; 1998 Mar; 28(3):504-9. PubMed ID: 9551690
[TBL] [Abstract][Full Text] [Related]
7. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
Tsukagoshi S
Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antitumor activity of a heterodinucleotide of BVDU and gemcitabine.
Cappellacci L; Franchetti P; Vita P; Petrelli R; Grifantini M
Nucleosides Nucleotides Nucleic Acids; 2008 May; 27(5):460-8. PubMed ID: 18569785
[TBL] [Abstract][Full Text] [Related]
9. Effect of a Solid Lipid Nanoparticle Formulation on the Bioavailability of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine After Oral Administration.
Valdes SA; Alzhrani RF; Lansakara-P DSP; Cui Z
AAPS PharmSciTech; 2020 Jan; 21(3):77. PubMed ID: 31970527
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines.
Bader Y; Hartmann J; Horvath Z; Saiko P; Grusch M; Madlener S; Maier S; Oehler L; Fritzer-Szekeres M; Heller N; Alken RG; Krupitza G; Szekeres T
Cancer Lett; 2008 Feb; 259(2):231-9. PubMed ID: 18023527
[TBL] [Abstract][Full Text] [Related]
11. A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-
Sun Y; Wang J; Hao K
Molecules; 2020 May; 25(9):. PubMed ID: 32397338
[TBL] [Abstract][Full Text] [Related]
12. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
[TBL] [Abstract][Full Text] [Related]
13. Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells.
Bouffard DY; Momparler LF; Momparler RL
Anticancer Drugs; 1991 Feb; 2(1):49-55. PubMed ID: 1958852
[TBL] [Abstract][Full Text] [Related]
14. Effect of 2',2'-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro.
Rockwell S; Grindey GB
Oncol Res; 1992; 4(4-5):151-5. PubMed ID: 1504375
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
Wu W; Sigmond J; Peters GJ; Borch RF
J Med Chem; 2007 Jul; 50(15):3743-6. PubMed ID: 17602464
[TBL] [Abstract][Full Text] [Related]
16. Synergistic action of tiazofurin and difluorodeoxycytidine on differentiation and cytotoxicity.
Ban J; Weber G
Biochem Biophys Res Commun; 1992 Apr; 184(2):551-9. PubMed ID: 1349474
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Egawa S; Unno M; Terasaki T
Pharm Res; 2012 Jul; 29(7):2006-16. PubMed ID: 22419259
[TBL] [Abstract][Full Text] [Related]
18. Genotoxicity kinetics in murine normoblasts as an approach for the in vivo action of difluorodeoxycytidine.
Morales-Ramírez P; Vallarino-Kelly T; Cruz-Vallejo V
Cancer Chemother Pharmacol; 2017 May; 79(5):843-853. PubMed ID: 28324147
[TBL] [Abstract][Full Text] [Related]
19. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
[TBL] [Abstract][Full Text] [Related]
20. Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells.
Ross DD; Cuddy DP
Biochem Pharmacol; 1994 Oct; 48(8):1619-30. PubMed ID: 7980627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
